Orbital Service, Moorfields Eye Hospital, London, EC1V 2PD, UK.
Eye (Lond). 2023 Nov;37(16):3406-3411. doi: 10.1038/s41433-023-02519-7. Epub 2023 Apr 15.
To evaluate presenting features of patients with orbital solitary fibrous tumours (SFTs), based on histological phenotype.
A retrospective case-note review was performed for demographics and presenting features for patients with orbital SFTs. The tumours were classified as "Group IA" hypocellular SFT phenotype, "Group IB" haemangiopericytoma phenotype and low mitotic activity, and high-grade "Group II" haemangiopericytoma phenotype with high mitotic activity.
Sixty-four patients (34 female; 53%) presented at a mean age of 42.2 years (median 38; range 19-82), with Group II patients presenting at an older age (mean 53 years). Median symptom duration was 12 months for Groups IA and IB, compared to 4 months for Group II, the commonest symptoms being proptosis (53%), diplopia (41%), periorbital swelling (31%), and altered vision (19%). Mean LogMAR was 0.17 (median 0.0; range -0.2-4), and 14% had ipsilateral optic neuropathy, with no significant difference between the three groups. Non-axial displacement was noted in 69%, a palpable mass in 45%, and reduced eye movements in 59%; choroidal folds and optic disc swelling were recorded in 12% and 9%. SFTs were mostly extraconal (59%), within the superior and superonasal quadrants (44%), with an average estimated tumour volume of 4.9 ml (median 3.6; range 0.31-14.5 ml).
SFTs may present with impaired visual function (∼15%), fundal abnormalities (a fifth), globe displacement (two-thirds), and reduced ocular motility (over a half). High-grade tumours tend to present more than a decade later, with a shorter duration of symptoms.
根据组织学表型评估眼眶孤立性纤维肿瘤(SFT)患者的临床表现。
对眼眶 SFT 患者的人口统计学和临床表现进行回顾性病例记录回顾。肿瘤分为“IA 组”细胞稀少型 SFT 表型、“IB 组”血管外皮细胞瘤表型伴低有丝分裂活性和高级别“II 组”血管外皮细胞瘤表型伴高有丝分裂活性。
64 例患者(34 例女性;53%)平均年龄为 42.2 岁(中位数 38 岁;范围 19-82 岁),II 组患者年龄较大(平均 53 岁)。IA 组和 IB 组的中位症状持续时间为 12 个月,而 II 组为 4 个月,最常见的症状是眼球突出(53%)、复视(41%)、眶周肿胀(31%)和视力改变(19%)。平均 LogMAR 为 0.17(中位数 0.0;范围-0.2-4),14%的患者同侧视神经病变,三组间无显著差异。69%的患者存在非轴向移位,45%的患者存在可触及的肿块,59%的患者存在眼球运动受限;12%的患者存在脉络膜皱褶,9%的患者存在视盘肿胀。SFT 主要位于眶外(59%),位于上象限和上象限(44%),平均肿瘤体积估计为 4.9ml(中位数 3.6ml;范围 0.31-14.5ml)。
SFT 可能表现为视力受损(约 15%)、眼底异常(五分之一)、眼球移位(三分之二)和眼球运动受限(超过一半)。高级别肿瘤往往在 10 多年后才出现,且症状持续时间较短。